Aims Resistant hypertension is associated with a high risk of cardiovascular disease,
chronic kidney disease, and mortality. Yet, its management is challenging. This study aims to …

Hypertension is highly prevalent and a major contributor to cardiovascular mortality and
morbidity. In spite of the availability of efficacious, safe and affordable anti-hypertensive …

Catheter-based renal artery denervation (RAD) is entering a new era. After the disappointing
results of SYMPLICITY-HTN 3 trial in year 2014, several technical and methodological …

BACKGROUND: The SPYRAL HTN-ON MED trial showed significant office and nighttime
systolic blood pressure (BP) reductions in patients with hypertension following renal …

National Heart Center/Saudi Heart Association 2023 Guidelines on the Management of
Hypertension - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI …

Renal denervation (RD) has been investigated as an invasive blood pressure (BP) lowering
treatment for hypertension (HTN). Resistant HTN (RHTN) has been defined as uncontrolled …

Recently, the STEP trial (Strategy of Blood Pressure Intervention in the Elderly Hypertensive
Patients) clearly demonstrated that intensive treatment with a systolic blood pressure (BP) …

Arterial hypertension is the most prevalent global modifiable risk factor for cardiovascular
morbidity and mortality. Despite the availability of numerous pharmacologic treatments …

This systematic review and meta-analysis was conducted to assess the randomized
controlled trial (RCT) evidence available for renal denervation (RDN) in uncontrolled arterial …

Hypertension is the most powerful risk factor of cardiovascular disease [1], and
antihypertensive treatment significantly reduces the rate of atherosclerotic cardiovascular …